FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “NeuroBo Pharmaceuticals, Inc. Announces Positive Recommendation from Independent Data Safety Monitoring Committee”
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) climbed over 8% in premarket trading after an independent Data Monitoring Committee reviewed safety data from 36 patients treated in the Phase 2/3 <-(two three) clinical trial of NeuroBo’s lead drug candidate, ANA001.
ANA001 is a proprietary oral niclosamide formulation being developed as a potential treatment for COVID-19 and based on the findings, the DMC recommended the continuation of the trial without modification.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company’s recently acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with COVID-19. Niclosamide has antiviral and anti-inflammatory properties, and a well-understood safety profile in humans.
For more information, please visit: NeuroBo Pharmaceuticals, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.